Form 4 Tracker
Keith Regnante

CHIEF FINANCIAL OFFICER · 2 filings · Latest: Feb 24, 2026

Keros Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
KROS
Keith RegnanteCHIEF FINANCIAL OFFICERFeb 18, 2026
Sale
$16.354,739$77.5K39,261